Sarepta’s industry-leading pipeline is comprised of programs in various stages of development. Currently, Sarepta has one gene therapy and three RNA-based therapies on the market in the United States.

Learn about our Products

Program Details
Information is current as of February 2026.

  • Program Name
  • Discovery/Preclinical
  • Clinical
#661b62
100
SRP-1001
#661b62
100
SRP-1003
#661b62
100
SRP-1002
#661b62
100
SRP-1004
#661b62
50
SRP-1005
#661b62
50
SRP-1007
#661b62
50
SRP-1006
#172a84
100
SRP-9003
(bidridistrogene xeboparvovec)

* HD = Huntington's Disease; SCA1 = Spinocerebellar ataxia type 1; SCA3 = Spinocerebellar ataxia type 3

Download PDF of Our Pipeline

For more information about our pipeline, please contact Sarepta's Patient Affairs team at [email protected].